6 research outputs found
Patient enrollment flow chart and the therapeutic course during the 1-year observation after the baseline in our RA cohort.
<p>HDA: high disease activity; MDA: moderate disease activity; LDA: low disease activity; csDMARDs: conventional synthetic disease-modifying antirheumatic drugs; bDMARDs: biological disease-modifying antirheumatic drugs.</p
Patients’ characteristics with disease activity (univariate analyses)<sup>*</sup>.
<p>Patients’ characteristics with disease activity (univariate analyses)<sup><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0175281#t005fn001" target="_blank">*</a></sup>.</p
Cumulative probability plots of changes in mTSS for 1 year in the ACPA-positive patients versus the ACPA-negative patients.
<p>ACPA: anti-citrullinated peptide antibodies; mTSS: modified total Sharp score.</p
Cumulative probability plots of actual radiographic progression assessed by mTSS (U/year) in the cohort (n = 198).
<p>mTSS: modified total Sharp score.</p
Prediction of CRRP in multiple logistic regression analysis (continuous variables)<sup>*</sup>.
<p>Prediction of CRRP in multiple logistic regression analysis (continuous variables)<sup><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0175281#t003fn001" target="_blank">*</a></sup>.</p
Prediction of CRRP in multiple logistic regression analysis (binary variables)<sup>*</sup>.
<p>Prediction of CRRP in multiple logistic regression analysis (binary variables)<sup><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0175281#t004fn001" target="_blank">*</a></sup>.</p